Overview
Asiri operates Sri Lanka's Asiri hospital network and a nationwide diagnostics business. The June quarter combined revenue growth with record June gross and net margins, although operating profit declined as operating margin narrowed. The key tension is strong underlying revenue and margin positioning against a share-price retreat not matched by fresh company disclosures.
Price performance
The share closed at LKR 32.10 on 1 September 2026. It fell 13.3% over three months versus a 4.5% decline in the ASPI, and was down 13.5% over one year while the index gained 3.6%.
The price sits 17.1% up from its 52-week low, with 20-day trading volume 52.3% above its 60-day norm. Recent volatility was below the company's own one-year level. The supplied news flow and filings do not account for the three-month underperformance.
Valuation
At 7.31 times earnings, Asiri trades at a substantial discount to the healthcare peer median of 19.29 times. Its 1.43 times book value is also below the sector median, while the latest audited ROE was 11.7%, supporting the case that the lower P/B is not simply explained by weak returns.
The stock has no trailing dividend yield, versus a 2.3% sector median. Dividend history records LKR 1.50 per share for FY2025 and LKR 2.50 for FY2022; the available record is too incomplete to establish a reliable payout trend. Sector valuation percentiles are not supplied.
News and sentiment
The supplied 90-day news metrics record one material article, all negative, relating to a CSE enforcement action dated 13 March 2026. Coverage is classified as normal, but there has been no company news in the last 30 days.
Financials
June gross margin was 51.0%, up from 50.9% a year earlier. June is structurally Asiri's weakest quarter for gross margin, yet this was the best result among seven comparable June quarters.
Operating margin narrowed to 20.3% from 23.4%, and operating profit fell year-on-year. Net margin nevertheless improved to 14.3% from 14.1%, ranking first among seven comparable June quarters, as the below-the-line charge reduced from LKR 810 million to LKR 570 million.
Revenue and net profit both grew year-on-year, while operating profit moved the other way, so the earnings gain was not wholly operational. Equity increased and the share count remained unchanged, preserving comparability of per-share data. Minority shareholders received a material share of group profit in the latest audited year, so group profit exceeds the amount attributable to listed shareholders.
Risks
Liquidity is the principal balance-sheet risk: the latest audited current ratio was 0.59, meaning current liabilities materially exceeded current assets. Total debt stood at LKR 14.0 billion, equivalent to gearing of 58.9% of equity attributable to owners.
Interest cover of 2.87 times leaves limited room for a higher finance burden. Cash conversion was 0.65 times operating profit, so reported operating earnings were not fully realised in cash during the latest audited year. Minority interests accounted for 9.3% of group profit, reducing the share of earnings available to ordinary shareholders.
Outlook
As at 1 September 2026, the next scheduled event is the September 2026 quarterly filing, expected between 11 November 2026 and 27 February 2027. It will supersede the June-quarter evidence and clarify whether the lower operating margin was offset again by smaller below-the-line charges.
The available data cannot establish the reason for the recent share-price decline or provide visibility on patient volumes, pricing, or the outcome of the enforcement action.